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During routine screening of the fermentation broths of soil fungi (Strepto-
myces spp.) for specific inhibitory effects on mouse mixed lymphocyte 
reactions (MLR), investigators of the Fujisawa Pharmaceutical Co., Ltd., 
Osaka, Japan, 19UO~ 1983, identified a product of Streptomyces tsukubaen-
sis, which exhibited powerful antilymphocytic and immunosuppressive 
activity (Goto et al., 1987). The isolated product, designated FK 506, 
although classified as a macrolide antibiotic, exhibited no growth inhibi-
tory effect on bacteria or yeast and showed only limited antifungal activity 
against Aspergillus Jumigatus and Fursarium oxysporum (Kino et al., 
1987a). Early investigations revealed that FK 506 was very effective in 
suppressing immune responses both in vivo and in vitro and that the 
effective concentration was usually 10 to 100 times lower than that of 
cyclosporin A (CsA) (Goto et al., 1987; Kino et al., 1987a,b). An initial 
report on the capacity of FK 506 to prevent organ (heart) allograft 
rejection in rats was presented by T. Ochiai at the 11 th International 
Congress of the Transplantation Society held in Helsinki in Angust, 1986 
(Ochiai et ai., 1987). Since then, there has been rapid progress in 
elucidating the mode of action of FK 506 and in characterizing its 
immunosuppressive properties, including its effects on allograft survival in 
various animal models (reviewed by Thomson, 1989, 1990). This has led to 
the clinical evaluation of FK 506 in human organ (liver, kidney, heart, 
small bowel) transplantation in the University of Pittsburgh (Starzl et ai., 
1989a,b, 1990; Todo et al., 1990a,b; Armitage et at., 1991; Shapiro et at., 
1991) and more recently, in 20 other centres in the United States, Europe 
and Japan. These centres are presently conducting prospective, random-
ized controlled trials of FK 506 in primary liver transplantation. 
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FK 506 shares many of the properties of CsA, a structurally unrelated 
fungal metabolite, but the former drug is considerably more potent. The 
two drugs share a very similar mode of action (Sawada et ai., 1987; Zeevi 
et al., 1987; Tocci et ai" 1989) which inhibits the'activation of CD4+T 
(helper) lymphocytes and the secretion of cytpkines crucial to the induc-
tion and expression of immune reactivity. What follows is an overview of 
the pharmacology and molecular action of FK 506. The molecular action 
of FK 506 was recently reviewed by Schreiber (1991) and Schreiber and 
Crabtree (1992), 
Physicochemical properties of FK 506 
FK 506 is a white crystalline powder at room temperature and dissolves 
readily in non-polar solvents, such as methanol, ethanol and chloroform 
(Tanaka et ai., 1987) but it is insoluble in polar solvents. The molecular 
formula of FK 506, deduced by elemental analysis and mass spectrometry, 
is C44H69N012H20 (molecular weight 822) (Tanaka et ai., 1987). Infra-
red spectral analysis has revealed the presence of hydroxy groups (3530/ 
em), carbonyl groups (1750,1730, 171O/cm) and an amide group (1650/ 
em). Further detailed structural analysis by nuclear magnetic resonance 
has identified two ketones, one lactone, one hemiketal, three O-methyls 
and five C-methyls with the remainder being 12 methylenes and 13 
methines. The structure of FK 506 is shown in Fig. 6,1. FK 506, a lactone 
with sugar substituents differs totally in structure from CsA, a cyclic 
peptide comprising 11 amino acids. 
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Fig. 6.1. The structure of FK 506 showing the immunophilin (FKBP) binding domain 
and the effector element. CsA is structurally dissimilar to FK 506. 
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FK 506 is relatively stable under normal laboratory conditions and 
has a melting point of 127-129°C. Maximal activity ofFK 506 is retained 
after storage for 6 months at 40°C, 3 months at 82% relative humidity, 3 
months under 500 Lux fluorescent light exposure and 24 months at room 
temperature (Tanaka et al., 1987). Reports of its synthesis first appeared in 
1989 (Harding et al., 1989; Siekierka et al., 1989). 
Pharmacokinetics of FK 506 in animals and man 
FK 506 is quantified in body fluids, following extraction of drug, by an 
enzyme-linked immunosorbant assay (ELISA), in which either a mono-
clonal or polydonal antibody is employed. In blood, most of the FK 506 is 
bound to erythrocytes (mean trough blood:plasma ratio 10: 1). The 
sensitivity limit is 20 pg/ml in plasma (Tamura et al., 1987). A modified 
ELISA, using a solid phase extraction method and a mouse monoclonal 
anti-FK 506 antibody for quantitation of FK 506 in human plasma, has 
been described more recently (Cad off et al., 1990). The extent to which the 
antibody cross-reacts with FK 506 metabolites is unknown. 
Monitoring of plasma FK 506 concentrations in the dog (Tamura et 
al., 1987) has shown that, at immunosuppressive doses (1.0 mg/kg per os) 
the trough level lies between 0.08 and 0.4 ng/ml, while at non-immuno-
suppressive doses, a lower trough concentration is observed. This indicates 
that the effective, prophylactic plasma trough level is between 0.1 and 
0.4 ng/ml (T odo et al., 1988; Ochiai et al., 1989). Coadministration of FK 
506 with CsA can reduce the threshold effective FK 506 trough level 
(Ochiai et al., 1989) and this may explain the synergy exhibited between 
these two drugs in experimental animals (Murase et al., 1987; Todo et al., 
1987; Ochiai et al., 1989) and reported earlier in in vitro models (Sa wada et 
al., 1987). In canine kidney recipients undergoing rejection, reduction in 
serum creatinine level and attenuation or disappearance of the cellular 
infiltrate during rejection was observed in FK 506-treated animals and 
was shown to correlate with an increase in FK 506 trough level (Ochiai et 
al., 1989). 
FK 506 is absorbed slowly after oral administration and distributed in 
various organs, induding lung, spleen, heart and kidney (Venkatara-
manan et al., 1990). Whilst absorption of CsA appears to be dependent on 
availability of bile in the gut, bile is unnecessary for FK 506 absorption 
(Jain et al., 1990). The majority of FK 506 appears to be metabolized by 
N-demethylation and hydroxylation in the liver and is then excreted in 
bile, urine and faeces within 48 h of administration (Venkataramanan et 
al., 1990, ] 991). Activity of cytochrome P-450, the mixed function oxidase 
system of isoenzymes that metabolizes CsA, is downregulated by FK 506 
both in vivo (Venkataramanan et al., 1990) and in vitro (Burke et al., 
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1990). This implies a possible mechanism whereby FK 506 affects the 
pharmacokinetics of CsA, which also depends on this degradation system. 
Studies aimed at determining the optimal route.of administration and 
dosage of FK 506 for clinical study were hampered by the severe toxic 
effects of the drug in dogs. Fortunately, the choice of method of drug 
delivery in the first clinical trial, i.e. 0.15 mg/kg intravenous (i.v.) over an 
hour soon after liver revascularization, followed by 0.075 mg/kg/12 h until 
the patient could eat, then oral doses of 0.15 mg/kg/12 h, was reasonably 
well tolerated (Todo et al., 1990a). With i.v. therapy, continuous instead of 
4-h infusions reduce the associated risks of transient renal and neuro-
logical dysfunctions, especially in high-risk patients (Abu-Elmagd et al., 
1991a,b). The i.v. doses used in man have required downward revision 
(Starzl et al., 1991a; Abu-Elmagd et al., 1991a,b). Peak plasma concentra-
tion is observed at the end of the infusion and then levels decline slowly 
over the next 24 h (Venkataramanan et aI., 1990, 1991). Plasma trough 
levels tend to be about 1 ng/ml, the effective immunosuppressive concen-
tration in vitro. The half-life ranges from 3.5 to 40.5 h, with a mean of 8.7 h 
(Venkataramanan et al., 1990). Drug absorption following oral adminis-
tration is highly variable. The mean bioavailability is about 25% (range 
6-57%). A peak plasma level of 0.4-3. 7 ng/ml is reached after 1-4 h of an 
oral dose at 0.15 mg/kg (Venkataramanan et al., 1990). The half-life ofCsA 
is prolonged in patients receiving FK 506, from a normal 6-15 h to 
26-74 h. This indicates that FK506 may affect CsA metabolism, a 
phenomenon demonstrated recently in vitro (Burke et al., 1990). 
Experience gained from studies in CsA-treated liver transplant pa-
tients indicates that alterations in the absorption and metabolism of CsA 
occur with changing liver function (Grevel & Kahan, 1989). Since FK 506 
and CsA share similar physical properties, the same issues might be 
expected to arise for FK 506. In five jaundiced patients with liver 
dysfunction, peak and trough FK 506 levels were higher than in patients 
with good hepatic function. Moreover, the half-life of FK 506 was 
increased and its clearance was reduced in patients with hepatic dysfunc-
tion (Jain et al., 1990). As a result, the overall bioa vailability of FK 506 
was expected to increase because of the greatly reduced intrinsic clearance 
(Venkataramanan et al., 1990, 1991). 
The full impact of hepatic dysfunction on FK 506 pharmacokinetics 
was not appreciated until clinical trials were well established (Abu-Elmagd 
et al., 1991a; Starzl et al., 1991a). In liver transplant recipients, whose 
grafts do not function well initially and/or fail to recover quickly, the daily 
i.v. dose of 0.15 mg/kg quickly leads to enormously high trough plasma 
levels (> 100 ng/ml fi'as been recorded), complete renal failure and neu-
rotoxicity, which can progress to mutism, convulsions and coma. Prompt 
dose reduction is required and guidance for this is provided by rapid turn 
around time in the plasma assays. Dose control of the i.v. FK 506 is easier 
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if the drug is given by constant infusion instead of the 2-h bolus, which was 
originally used. 
Even with well-functioning liver grafts, or in kidney and heart 
recipients whose hepatic function is normal, the University of Pittsburgh 
patients are now given a smaller i.v. dose of 0.075 or 0.10 mg/kg/day, 
instead of the O.IS mg/kg originally employed. The larger doses cause 
unacceptable increases in plasma levels and can cause acute renal failure 
or neurotoxicity (Abu-Elmagd et ai., 1991a; Starzl et ai., 1991a). Failure to 
make these revisions constitutes an unnecessary risk. Plasma levels of 
3-S ng/ml can be accepted during the peri-operative period of constant 
drug infusion, if there is no evidence of toxicity, but otherwise the doses 
should be reduced to < 3 ng/ml. 
, A number of interactions of FK S06 with other drugs have been 
observed. Trough plasma concentrations of FK S06 are increased by co-
administration of erythromycin, fluconazole and clotrimazole, whilst the 
effects of phenytoin, phenobarbital and acyclovir on FK S06 pharmaco-
kinetics are currently being investigated. 
Antilymphocytic activity of FK 506 
The effects of FK 506 on T-cell responses, in vitro and in vivo, and the 
influence of the drug on gene expression Jand cytokine production are 
summarized in Table 6.1. Studies that are aimed at elucidating the 
immunosuppressive action of FK S06 have shown that the drug is very 
effective in suppressing both alloantigen- and T-cell mitogen-induced 
lymphocyte proliferation. The SO% inhibitory concentrations (ICso ) of 
FK S06 and CsA for human MLR are 0.21 nM and 20 nM respectively and 
for phytohaemagglutinin (PHA)-induced responses 8.6 nM and 7S0 nM 
respectively (Thomson, 1989; Yoshimura et ai., 1989a). Thus, compared 
with PH A-induced T-cell responses, those evoked by alloantigens are 
more FK S06-sensitive (Yoshimura et ai., 1989a; Woo et ai., f990b; Zeevi 
et ai., 1990). In contrast, anti-CD28-induced responses are FK 506 
insensitive (Kay & Benzie, 1990; Bierer et ai., 1991). Taken together, these 
observations reflect inherent differences between CD3- and CD28-activa-
tion pathways and their differential sensitivities to FK S06. Like CsA, FK 
S06 inhibits T-cell activation mediated not only by the T-cell recep-
tor-CD3 complex, but also via another cell surface molecule, C02 (Bierer 
et al., 1991). 
Delay in the addition of FK S06 to mitogen-stimulated cultures 
results in reduction of its antilymphocytic activity (Kay et ai., 1989), 
indicating a selective'influence of FK 506 on early events in T-cell 
activation. The latter appear to include Ca2 + mobilization, protein kinase 
C (PKC) activation, cytokine gene transcription, cytokine secretion and 
cytokine-receptor expression, all of which occur within the first 2 h of T-
, t 
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Table 6.1. Effects of F K 506 on T cells 
Phenomenon Effect Reference 
Lymphocyte responses 
in vitro 
MLR (human. mouse) Kino et al .. 1987b; Sawada et al .. 1987; 
Yoshimura et al .• 1989a 
Con A. PH A-induced Sawada et al., 1987; Yoshimura et al.. 
lymphocyte proliferation 1 989a; Woo et al .. 1 990b 
Tc induction Sawada et al., 1987; Yoshimura et al .. 
1989a 
Tc function Sawada et a/., 1987; Yoshimura et al,. 
1989a 
Ts induction Yoshimura et a/., 1989a 
Cell-mediated immunity 
DTH (MSSA) l Kino et al .. 1987a 
Graft-versus- host l Kino et al .• 1987a 
disease 
Host-versus-graft Morris et al., 1989 
popliteal lymph node 
assay 
T -dependent humoral 
response: 
Alloantibody l Propper et al .• 1990 
Anti-SRSe Ab l Woo et al .. 1990a 
Ex vivo Con A-induced l Woo et al .. 1990c 
spleen cell proliferation 
, ' Lymphokine production 
I L-1 
IL-2 l Kino et al .. 1987b; 
Sawada et al .• 1987 
IL-3 Kino et al .. 1987b 
IL-4 
IL-5 
IL-6 NC Yoshimura et al .. 1989b 
INFi' l Kino et al., 1 987b 
GM-CSF l Kino et al., 1987b 
Lymphokine receptor expression 
IL-2R Kino et al., 1987b; Yoshimura et aI., 
1989a,b; Woo et a/., 1990b 
r 
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Table 6.1. Continued 
Phenomenon Effect Reference 
MHC antigen expression 
HLA-DR on activated T t Woo et al., 1990b 
cells 
HLA-DR on monocytes NC Woo et al., 199Gb 
Gene expression 
IL-h, fJ NC Tocci et al., 1989 
IL-2 t Tocci et a/., 1989 
IL-3 t Tocci et al., 1989 
IL-4 t Tocci et al., 1989 
IL-10 NC Wang et al., 1991 
GM-CSF t Tocci et al., 1989 
TNF:x t Tocci et al., 1989 
IFNy l Tocci et al., 1989 
c-myc t Tocci et al., 1989 
c-fos NC Tocci et al., 1989 
TfR NC Tocci et al., 1989 
IL-2R :x-chain NC Tocci et al., 1989 
TNFfJ NC Tocci et al., 1989 
MHC class I HLA 8-7 NC Tocci et al., 1989 
FKBP 
TCRfJ-chain Kay et al., 1989 
Abbreviations: l, decrease; i, increase; NC, no change; ?, unclear; DTH, delayed-
type hypersensitivity; TfR, transferrin receptor; FKBP, FK 506-binding protein; 
MLR, mixed lymphocyte reaction; SRBC, sheep red blood cells. 
cell activation. 
The generation of cytotoxic T lymphocytes (CTL) and suppressor T 
cells during human MLR is inhibited by FK 506 (Yoshimura et al., 1989a), 
but the cytolytic activity of CTL against target cells during the effector 
phase is FK 506 resistant (Sawada et al., 1987; Yoshimura et al., 1989a). 
This indicates that FK 506 affects only the early induction phase of CTL 
development and has no effect on antigen recognition by CTL or on the 
cytolytic mechanism which results in target-cell destruction. Moreover, 
Zeevi et af. (1990) have reported that FK 506 does not affect human CTL 
differentiation or maturation from pre-effector to effector CTL. The recent 
finding that FK 506 has little or no effect on natural killer (NK) cell 
numbers or function or on antibody-dependent cytotoxicity (Markus et 
al., 1991; Wasik et al., 1991), suggests beneficial sparing of natural 
immunity against infectious agents. 
Information concerning effects of FK 506 on processing and presenta-
tion of antigen by antigen-presenting cells (A PC), is presently very limited. 
.. 
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Nevertheless, FK 506 concentrations which strongly inhibit antigen 
purified protein derivative (PPD)-induced human T-cell proliferation, 
have little effect on antigen processing and presentation by human blood 
monocytes (Woo et ai., 1990a). There is evidence, however, that FK 506 
may impair alloantigen processing/presentation in human MLR (Thomas 
et al., 1990). Cooper et al. (1991) observed that any effect ofFK 506 on the 
presentation of microbial (Listeria) antigens by murine macrophages 
could be ascribed to drug carryover to the readout system (T-cell 
proliferation). 
Experimental data concerning the inhibitory effect of FK 506 on 
mitogen- and alloantigen-induced T-cell responses in culture, indicate that 
FK 506, like CsA, exerts its primary influence on CD4 + (helper) T cells, 
with consequent effects on other cell types. Several studies have demon-
strated that FK 506 inhibits the expression of the activation molecules 
interleukin (IL)-2R, MHC class II antigens and transferrin receptor (TfR), 
in a dose-dependent manner (Yoshimura et al., 1989a; Woo et al., 1990b). 
These effects, however, may be secondary to the potent inhibitory action of 
FK 506 on IL-2 production and to the reduction of its consequent, 
autocrine effect on the expression of IL-2R. Considered in conjunction 
with the reported failure of FK 506 to inhibit IL-2R mRNA expression 
(Tocci et ai., 1989), these observations suggest post-transcriptional inhibi-
tion of IL-2R expression by the drug. 
Effects of FK 506 on early T -cell activation genes 
FK 506 strongly inhibits expression of mRNA for early T-cell-activation 
genes, including those encoding IL-2, IL-3, IL-4, IFNy, granulocyte-
monocyte-colony-stimulating factor (GM-CSF) and c-myc (Tocci et ai., 
1989; Dumont et al., 1990b; Metcalfe & Richards, 1990). It is likely that 
the generation or transmission of a common activation signal for these 
genes is inhibited by FK 506, as prevention of gene expression by the drug 
is unaffected by the nature of the inducers used. On the other hand, recent 
studies have shown that FK 506 does not inhibit production of human IL-
6 (Yoshimura et ai., 1989b) and may spare IL-tO (cytokine synthesis 
inhibitory factor) gene transcription by cloned murine helper T cells (T H2) 
in vitro, whilst suppressing concomitant IL-4 mRNA production by these 
cells (Wang et al., 1991). Thus, differential interference with cytokine gene 
expression may be an important mechanism whereby FK 506 and CsA 
inhibit immune-cell activation. Inhibition of gene expression by FK 506 is 
specific to early genes. No inhibition of constitutively expressed T-cell 
receptor (TCR)-/3, MHC class I human leukocyte antigen (HLA)-B7, 
GPDH or late-phase genes, like IL-2R, TfR and tumour necrosis factor 
(TNF)-/3 (Kay et al., 1989; Tocci et al., 1989) is observed. Inhibition and 
superinduction, respectively, of krox 20 and krox 24 mRNA by FK 506 in 
----_._---_ .. _----
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murine lymphocytes (Metcalfe & Richards, 1990) may be of particular 
significance, since these genes encode proteins which are likely to regulate 
gene expression. In contrast to its influence on Iymphokine gene expres-
sion and protein secretion, no inhibitory action of FK 506 on mono kine 
gene expression (including IL-la or IL-l,B mRNA synthesis) or monokine 
production (TNFa and IL-6) after lipopolysaccharide (LPS) stimulation 
or human monocytes has been observed (Tocci et al., 1989). 
Experiments designed to ascertain the influence of FK 506 prior to 
gene transcription have shown that FK 506 does not affect Ca2 + mobiliza-
tion (Bierer et al., 1990), phosphatidylinositol turnover (Fujii et al., 1989) 
or PKC activities (Gschwendt et al., 1989) following binding of the antigen 
receptor. The target of FK 506 is thus probably a later event elicited by the 
T-cell antigen receptor (TCR) pathway and/or a separate activation 
pathway distinct from phosphoinositol breakdown. 
Influence of FK 506 on gene transcription 
The precise molecular events which occur in the cytosol during T-cell 
activation and lead eventually to gene activation within the nucleus are 
still unclear. Following cytoplasmic biochemical changes, one or more 
signals pass into the nucleus to influence the IL-2 gene, expression of 
which is regulated by a transcription initiation site (Durand et al., 1987; 
Williams et al., 1988). The nucleic acid sequence of the IL-2 enhancer 
(regulatory) region has been identified and several cis-acting transcrip-
tional segments of this region that bind different nuclear factors have been 
investigated (Williams et al., 1988; Muegge & Durum, 1990). Two 
sequences of this enhancer, - 285 to - 255 and - 93 to - 63 activate a 
linked promoter in response to signals generated from the antigen receptor 
(Durand et al., 1987) (Fig. 6.2.). These two regions are bound by two 
distinct nuclear factors to protect them from DN Ase digestion (Durand et 
al., 1987). One of these nuclear factors, NFIL-2A, which is present in both 
IL-2R 
~ ______ ~K~ ____________ ~w~ 
400 300 200 100 0 bp 
~f ____ -L ____ -LI ____ -L ____ ~f ____ ~ ____ ~f ____ ~ ____ ~f 
Fig.6.2. IL-2 and IL-2R gene promotor sequences, showing the binding sites of nuclear 
regulatory proteins. 
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activated and non-activated T cells, binds to the regulatory site identified 
in the IL-2 enhancer between - 93 and - 63. This sequence is referred to 
as antigen receptor response element-1 (ARRE-l) (Fig. 6.2), since it can 
only be activated through the TCRjCD3 pathway and not by phorbol 
myristate acetate (PMA) which activates PKC. The IL-2 gene promoter is 
then activated by the sequence protected from DNAse digestion, once an 
activation signal is elicited in the TCR. In contrast, the constitutive 
activity of the IL-2 promoter when the NFIL-2A binding is disrupted by 
mutation implies that NFIL-2A exerts a negative signal in resting T cells 
(Nabel et al., 1988). Since NFIL-2A is present in both activated and non-
activated cells, its presence and activity may not be influenced by 
immunosuppressive agents. A second antigen receptor response element 
(ARRE-2) present between - 285 and - 255 of the IL-2 enhancer is 
protected from DNAse by the nuclear factor of activated T celis-(NF AT) 
1, which is only expressed in activated T cells (Shaw et al., 1988). There is 
evidence that deletion of the NF AT binding site significantly impairs 
activity of the IL-2 enhancer (Durand et al., 1987). Moreover, the increase 
in NF AT binding activity in nuclear extracts of activated T cells (Shaw et 
al., 1988) and the appearance of NF A T about 10 min before the earliest 
detectable IL-2 mRNA implies that activation of the IL-2 gene is 
dependent on prior activation of NF A T. Cooperation between NF AT and 
NFIL-2A results in full enhancer activity, though each binds to a different 
sequence. Recent studies by Granelli-Piperno et al. (1990) have shown that 
the binding of NF AT to the transcriptional element is suppressed by FK 
506, thereby inhibiting IL-2 gene activation and consequently, lympho-
kine production. 
A third sequence, the AP-l binding site, which is responsible for IL-2 
transcription in response to PMA, is identified at position 240. Am~ 1 is 
the cellular homologue of the protein product of the v-jun oncogene 
(Ryder et al., 1988). Binding of AP-l to the AP-l binding site makes a 
normally unresponsive promoter respond to agents that activate PKC. A 
functional AP-l site in the IL-2 gene suggests a response to signals 
emanating from the TCR and to signals initiated by the activation of PKC. 
While the binding of AP-l to its binding site has been shown to be 
markedly reduced by FK 506 in EL 4 lymphoma cells (Granelli-Piperno et 
al., 1990), its transcriptional enhancing activity is not affected by FK 506 
in human synovial fibroblasts. 
Activation of the IL-2R gene is also essential for commitment of T 
lymphocytes to cell division and immunological functions. A binding site 
for the PMA-responsive transcriptional factor NF-kB was localized 
between - 255 and - 268 of the IL-2R transcription initiation site. 
Granelli-Piperno et al. (1990) reported recently that FK 506 had only a 
slight inhibitory effect on NF-kB binding, which is consistent with the 
minimal effect of FK 506 on IL-2R mRNA expression discussed earlier. 
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Role of FKBP in immunosuppression 
A novel class of cytosolic proteins of 'immunophilins' has become the 
focus of attention with regard to the mechanism of action of FK 506 and 
CsA. Two families of immunophilins have been identified, namely the 
cyclophilins (predominant member cyclophilin A) and the FK 506-
binding proteins (FKBPs) (predominant member FKBP 12) which are 
believed to play essential roles in the immunosuppressive actions of CsA 
and FK 506 respectively (Harding et al., 1989; Siekierka et al., 1989; Maki 
et al., 1990). Although their physiological role is unknown, both proteins 
possess peptidyl-prolyl cis-trans isomerase (PPlase) activity, that catalyses 
the slow cis-trans isomerization of ala-pro bonds in oligopeptides and 
a~elerates slow, rate-limiting steps in the folding of several proteins 
(Fischer et al., 1989). The PPlase activity of cyclophilin and FK BP is 
strongly inhibited by their respective ligands (Fischer et al., 1989; Siek-
ierka et al., 1989b), suggesting that PPlase activity may playa role in 
lymphocyte activation. 
FK 506 binds with high affinity to FKBP (Harding et al., 1989; 
Siekierka et al., 1989), a heat-stable cytosolic component with a molecular 
weight (10 12 kD) lower than cyclophilin (17737 D) (Siekierka et al., 
1989; Palaszyncki et al., 1991). No specific binding of FK 506 to purified 
calf thymus cyclophilin can be detected (Siekierka er al., 1989) and anti-
cyclophilin antibody does not cross-react with bovine or human FKBPs 
(Harding et al., 1989). Cloning of FKBP (Standaert et al., 1990; Tropschug 
et al., 1990) has revealed that, despite their common enzymatic properties, 
FKBP and cyclophilin have dissimilar sequences. 
The first 16 residues of human FKBP are identical to the correspond-
ing bovine sequence (Harding et al., 1989). cDNA of human lymphocyte 
FKBP has been synthesized and binds with mRNA species of 1.8 kb 
isolated from brain, lung, liver, placenta and leukocytes (Maki et al., 1990; 
Standaert et al., 1990), demonstrating the ubiquitous nature of this 
protein. The level of FKBP mRNA in (leukaemic) Jurkat T cells is, 
however, unaffected by cell activation stimulated through phorbol esters 
and ionomycin (Maki et al., 1990). Inhibition of FK BP's PPlase activity is 
specific to the binding of FK 506 (or the structurally related macrolide 
rapamycin), while inhibition of cyclophilin's PPlase activity is specific to 
CsA (Siekierka et al., 1989b; Dumont et al., 1990a). Although binding of 
the drug by its receptor (or 'immunophilin') inhibits isomerase activity. 
recent results indicate that the immunosuppressive effects of FK 506 and 
CsA result from the formation of complexes between the drug and its 
respective isomerase (Liu et al., 1991). Both FK 506-FKBP and CsA-cyc-
lophilin complexes have been shown to bind specifically to three polypep-
tides - calmodulin and the two subunits of caJcineurin (a Ca2 + -activated, 
serine-threonine protein phosphatase). In each case, the interaction of the 
.. 
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immunophilin appears to be with calcineurin (Fig. 6.3). The drug-immun-
ophilin complexes have been shown to block the Ca 2 + -activated phospha-
tase activity of calcineurin (Liu et ai., 1991). Thus, calcineurin appears to 
be the target of the drug-immunophilin complexes: 
A second, key observation in unravelling the molecular action of FK 
506 is that the drug-immunophilin complexes block Ca2 + -de,pendent 
translocation of the pre-existing, cytoplasmic component of NF AT to the 
nucleus (Flanagan et al., 1991). The nuclear component of NF A T is 
transcriptionally inactive in all cells other than activated T lymphocytes 
(see above) and is induced by signals from the TCR. Its appearance is not 
blocked by FK 506 or CsA. Current thinking is that FK 506 and CsA 
block dephosphorylation of the cytoplasmic component of NF A T which is 
required for its translocation to the nucleus (Fig. 6.4). In the absence of 
both nuclear and cytoplasmic components, binding ofNF AT to DNA and 
transcriptional activation of the IL-2 gene is suppressed. 
Conclusion 
It is now clear that FK 506 and CsA are pro-drugs and that their 
pharmacological action, resulting in immunosuppression, is dependent on 
binding to the appropriate immunophilin (FKBP or cyclophilin, respec-
tively). This results in modulation of the enzymic activity of the protein 
phosphatase calcineurin which, in turn, may impair translocation of the 
cytosolic component of the IL-2 gene transcription factor NF AT to the T-
cell nucleus. Several key issues remain to be resolved, including the 
physiological role of calcineurin. Elucidation of these and related molecu-
lar events underlying T-cell activation will play an important role in the 
design of future clinical immunosuppressive agents. 
8 
Fig. 6.3. Within the T lymphocyte, the FK 506-FKBP (FK 506 binding protein) 
complex binds with high affinity to calcineurin-calmodulin to form a pentameric 
complex which interferes with Ca2+ -dependent signalling pathways. Recent observa-
tions indicate that calcineurin (a protein phosphat~seF is the target of the FK 
506-FKBP complex. CaM, calmodulin; CNA, calcineurin A; CNB, calcineurin B. 
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IL-2 .-J gene 
transcription 
Cytoplasm 
Nucleus 
Fig. 6.4. Influence of FK 506 on signal transduction within T cells. FK 506 blocks 
translocation of the pre-existing cytoplasmic component of NF AT (8) to the nucleus 
by acting either on a Ca 2 + signalling pathway or on translocation following the 
action of this pathway. Both components of NF AT are required for DNA binding 
and activation of the IL-2 gene. TCR, T-cell receptor; TK, tyrosine kinase: PLC, 
phospholipase C: PKC, protein kinase C; A, induced nuclear component of NFAT; 
B, existing cytoplasmic component of NF AT. 
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